in the article “Use of Next-Generation Sequencing in the regulated domain of drug development“, Pistoia Alliance’s Keith Nangle and Mike Furness discuss how Next-Generation Sequencing is moving quickly from early research into the regulated domains of drug development, diagnostic development, and clinical decision-making.

This article summarises some of the technical and regulatory challenges posed by these technologies and the efforts being made to address them.